PSA as an intermediate end point in clinical trials
Author:
Publisher
Springer Science and Business Media LLC
Subject
Urology
Link
http://www.nature.com/articles/nrurol.2009.130.pdf
Reference10 articles.
1. Hussain, M. et al. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J. Clin. Oncol. 27, 2450–2456 (2009).
2. Petrylak, D. P. et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99–16. J. Natl Cancer Inst. 98, 516–521 (2006).
3. Armstrong, A. J. et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 25, 3965–3970 (2007).
4. Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148–1159 (2008).
5. Bubley, G. J. et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 17, 3461–3467 (1999).
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An overview of translational prostate cancer cohorts for prognostic and predictive studies;Histopathology;2018-12-18
2. Drug discovery in advanced prostate cancer: translating biology into therapy;Nature Reviews Drug Discovery;2016-07-22
3. Modeling and Analysis of Hormone and Mitogenic Signal Integration in Prostate Cancer;2016-06-13
4. Comprehensive validation of published immunohistochemical prognostic biomarkers of prostate cancer—what has gone wrong? A blueprint for the way forward in biomarker studies;British Journal of Cancer;2014-11-25
5. Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib;JNCI: Journal of the National Cancer Institute;2014-03-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3